You are here » Home » Companies » Company Overview » Jubilant Life Sciences Ltd

Jubilant Life Sciences Ltd.

BSE: 530019 Sector: Health care
NSE: JUBILANT ISIN Code: INE700A01033
BSE 11:55 | 21 Nov 713.00 -17.60
(-2.41%)
OPEN

724.75

HIGH

729.25

LOW

707.30

NSE 11:44 | 21 Nov 710.25 -18.00
(-2.47%)
OPEN

729.90

HIGH

734.10

LOW

705.40

OPEN 724.75
PREVIOUS CLOSE 730.60
VOLUME 5549
52-Week high 1039.00
52-Week low 617.45
P/E 39.48
Mkt Cap.(Rs cr) 11,358
Buy Price 712.20
Buy Qty 46.00
Sell Price 713.00
Sell Qty 7.00
OPEN 724.75
CLOSE 730.60
VOLUME 5549
52-Week high 1039.00
52-Week low 617.45
P/E 39.48
Mkt Cap.(Rs cr) 11,358
Buy Price 712.20
Buy Qty 46.00
Sell Price 713.00
Sell Qty 7.00

Jubilant Life Sciences Ltd. (JUBILANT) - Chairman Speech

Company chairman speech

Dear Fellow Shareholders

We have reported a record year in terms of sales and profitability led by strongperformance in Specialty Pharmaceuticals and Life Science Ingredients businesses. We havea well-defined strategy of being closer to our customers with an integrated value chainto have a de-risked business model with a diversified portfolio and strong manufacturingcapabilities from fully compliant sites. We are focused on driving business growth inSpecialty Pharmaceuticals and better utilisation of our assets in all our businesses.

The International Monetary Fund (IMF) expects global growth to rise to 3.9% in 2018 asglobal economic activity starts picking up through recovery in investments. According tothe IMF US growth has picked up in CY 2018 to an estimated 2.9%. Exports & consumerspending has provided a substantial boost to US GDP. The World Bank group report on"Global Economic prospects" states that investments trade and commodity pricesare rebounding which is expected to have a positive effect on growth going forward.

Investment bank Goldman Sachs forecasts India's GDP growth at 7.6% for FY 2018-19 andat 8.3% for FY 201920 which would make India the world's fastest-growing economy in FY2018-19. The Government is injecting a fair amount of stimulus into the economy andexports have also picked up considerably. Sturdy growth in global economy is expected toprovide an impetus to India's exports.

In India the first half of FY 2018 has witnessed the implementation of the landmarkGoods and Services Tax (GST). In addition the economy witnessed a recovery from theimpact of demonetisation which was announced in FY 2017. These two major structuralchanges are expected to provide immense benefits to the long-term growth trajectory of thecountry. Satisfactory monsoon has led to an improvement in agricultural and rural incomewhich is expected to help drive consumption. Other favourable indicators such as moderateinflation levels anticipated growth of industrial sector greater stability in GSTrecovery in investment levels and ongoing structural reforms are also positive factorswhich could propel India's economy to grow at an accelerated pace in the coming years.However this could be offset by increase in crude oil prices and increasing levels ofprotectionism in some countries.

The Indian pharmaceutical market is the third largest in the global pharmaceuticalindustry in terms of volume as per report by the India Brand Equity Foundation. India isalso the second largest contributor of global biotech and pharmaceutical workforce andlabor costs here are lower than other manufacturing hubs. India also has the secondhighest number of US FDA approved facilities outside the US which is a testament to thehigh quality and compliance which Indian pharmaceutical companies adhere to.

According to the Evaluate Pharma's annual 'World Preview' the global pharmaceuticalindustry is set to reach US$ 1.06 trillion by 2022. The growth of complex therapeuticareas is projected to outpace the growth of the overall pharmaceutical market emphasisingthe importance of increased R&D in the value chain. On the other hand variousdynamics in the international markets are eroding value from pure generic plays such asconsolidation among distributors and pharmacy chains increased product approvals andresultant competition in the generics space drop in new launch sales and increasing pricecontrol and protectionism in various global markets.

Shyam S Bhartia Hari S Bhartia
Chairman Co-Chairman and Managing Director